The world’s first and only MDR-certified Kidney cancer AI solution!
BMVision: Kidney offers an unparalleled accuracy in the detection, classification and quantification of renal lesions, enhancing and supporting radiologists in early discovery while saving valuable time and increasing inter-radiologist agreement rates.
High sensitivity
High accuracy
Improved efficiency by up to
Enhanced agreement
Problem
Rising incidence, late detection and inconsistent reads make kidney cancer easy to miss.
Kidney cancer incidence is on the rise
Expected to experience a rapid surge in incidence rates, particularly among younger demographics, making it one of the most rapidly growing cancers in the next two decades.
Late stage detection can be a death sentence
Reduced treatment options and high chance of metastases present poor survivability for Kidney cancer patients detected at the later stages.
60% of Kidney cancers are diagnosed incidentally
With kidney lesions being present in almost every adult it can be difficult to discern what needs attention and what is truly benign even for Kidney cancer specialists.
Increased inter-reader variability
Leading to mis-diagnosis, inconsistency and unnecessary downstream impact on the patient journey and outcomes.
Product Features
Product Feature 1
Automated lesion detection, classification and segmentation
Accurately detect lesions as small as 5 mm.
Utilise automated 3D lesion boundary segmentation
Automatically classify lesions, aiding in differentiation and improving diagnostic confidence.
Product Feature 2
Automated Quantification with Enhanced Dimensional Analysis
Automatically quantify and localise kidney lesions in CT images for consistent assessments.
Get two measurements: true longest dimension and three orthogonal dimensions.
Help radiologists make efficient and accurate assessments.
Product Feature 2
Automated Reporting for Enhanced Efficiency
Generate concise finding summaries for efficient review.
Results presented in an easy-to-understand format, facilitating clear explanations.
Access editable functions to add detail and personalise reports as needed.
Curious to learn more?
Contact us by booking a demo today
Meet the team
Learn about our Solutions tailored to your needs
Value
A high accuracy and efficient solution for supporting kidney lesion detection and assessment
Clinical performance of BMVision Kidney has been validated in a study performed by 6 radiologists at Tartu University Hospital. For more detailed information, read our article in Nature Communications Medicine.
Increase your efficiency and get time back by automating lesion measurements
Radiologists working with BMVision automated solutions take 33% less time on average to detect, measure and report malignant Kidney lesions from CT scans.
On average, 81% reduction of time needed to report malignant lesions per Kidney cancer patient.
Working with BMVision shows a 2.2% and 5.3% reduced error in lesion measurement respectively for malignant and benign lesions.
A highly sensitive and accurate diagnostic solution for Kidney cancer and lesion detection
Up to 25% fewer malignant lesions missed in kidney cancer patients.
Radiologists, in combination with BMVision, achieved a 99.2% sensitivity in detecting patients with kidney cancer.
Increased benign and malignant lesion detection resulting in 32% and 25% fewer lesions missed respectively.
Reduce variability between readers in lesion detection and assessment
Radiologists using BMVision showed a 3.8% higher agreement rate in malignant lesions detection.
Disagreement in malignant lesion detection decreased by 34.3%.
Diagnostic consensus amongst radiologists increased by 23%, notably enhancing agreement on lesion nature between benign and malignant lesions.
An overall 27% reduction in disagreement between radiologists regarding lesion classification.
